• PDF / 169,194 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 73 Downloads / 180 Views

DOWNLOAD

REPORT

---

1

S

Leukocytoclastic vasculitis: case report A 60-year-old man developed leukocytoclastic vasculitis during treatment with dabigatran etexilate. He started receiving dabigatran-etexilate [Pradaxa] [indication, dosage and route not stated]. Approximately 1 month after starting dabigatran etexilate, he experienced vasculitic rash on both legs. Additionally, he had been receiving unspecified long-term medications. He was diagnosed with leukocytoclastic vasculitis. Dabigatran etexilate was discontinued. Subsequently, leukocytoclastic vasculitis resolved. The case was reported to the New Zealand Medicines and Medical Devices Safety Authority. Author comment: "Medsafe is highlighting a possible risk of vasculitis with the use of dabigatran." New Zealand Medicines and Medical Devices Safety Authority. Possible risk of vasculitis with dabigatran (Pradaxa) Internet Document : 14 Nov 2019. Available from: URL: https://www.medsafe.govt.nz/safety/Alerts/Dabigatran.asp - New 803436256 Zealand

0114-9954/19/1781-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved

Reactions 30 Nov 2019 No. 1781